National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No.1 Dahua Road, Dongdan, Beijing 100730 P.R. China.
Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P.R. China.
Biochem Soc Trans. 2020 Oct 30;48(5):2295-2305. doi: 10.1042/BST20200653.
The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.
miR-21 在各种肝脏疾病发病机制中的作用，以及在循环中检测 microRNA 的可能性，使其成为非侵入性检测的潜在生物标志物。在这篇综述中，我们总结了细胞外 miR-21 在肝脏疾病患者临床管理中的潜在应用，并将其与当前的临床实践进行了比较。miR-21 对肝癌具有筛查和预后价值。在肝硬化中，miR-21 可能作为鉴别诊断和预后的生物标志物。miR-21 也是肝炎严重程度的潜在生物标志物。我们阐明了 miR-21 检测可以达到预期性能的疾病情况。尽管 miR-21 是肝脏疾病的关键调节因子，但 microRNAs 在复杂的调控网络中相互协调。因此，在某些临床情况下，miR-21 与其他 microRNAs 或经典生物标志物联合使用时，其性能更佳。
